Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HC022 in Systemic and Cutaneous Lupus Erythematosus
NCT07306585Phase 1Not yet recruiting
- Start
- Dec 2025
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HC022 in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) (4 arms). Primary endpoint: Adverse Events at 141 days. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
HC022
03
Conditions
systemic lupus erythematosus (SLE)cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on NCT07306585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07306585.